Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus.
von Spee-Mayer C, Siegert E, Abdirama D, Rose A, Klaus A, Alexander T, Enghard P, Sawitzki B, Hiepe F, Radbruch A, Burmester GR, Riemekasten G, Humrich JY.
von Spee-Mayer C, et al. Among authors: hiepe f.
Ann Rheum Dis. 2016 Jul;75(7):1407-15. doi: 10.1136/annrheumdis-2015-207776. Epub 2015 Aug 31.
Ann Rheum Dis. 2016.
PMID: 26324847